Search clinical trials for: treatment-induced myelosuppression

Total 43 results

Wuhan Union Hospital, China
Wuhan TongJi Hospital; Wuhan Central Hospital

Not yet recruiting

Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies

Infections | Hematologic Neoplasms | Anemia | Bleeding | Thrombocytopenia | Neutropenia

China
Wuhan Union Hospital, China

Not yet recruiting

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Infections | Acute Myeloid Leukemia | Anemia | Bleeding | Thrombocytopenia | Neutropenia
LI YAN

Not yet recruiting

Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression

Non-small Cell Lung Cancer
Pfizer

Not yet recruiting

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

Breast Cancer
G1 Therapeutics, Inc.

Recruiting

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Extensive-stage Small-cell Lung Cancer

Spain, Greece, Turkey, Poland, Georgia, Austria, Belgium, Bulgaria, Germany, Hungary
Sun Yat-sen University
JIANGSU JIBEIER PHARMACEUTICAL CO.,LTD

Not yet recruiting

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma | Chemotherapy | Myelosuppression | Leucogen

China
Pfizer

Not yet recruiting

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

Breast Cancer
UNC Lineberger Comprehensive Cancer Center
G1 Therapeutics, Inc.

Recruiting

Study of Trilaciclib and Lurbinectidin

Lung Cancer | Small-cell Lung Cancer

United States
Peking University Third Hospital

Recruiting

Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer

Rectal Cancer Stage II | Rectal Cancer Stage III

China
Moscow Clinical Scientific Center

Recruiting

A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations (Def_Special)

Breast Cancer | Solid Tumor | Gastrointestinal Cancer | Gynecological Malignancies | High-Risk Cancer | Myelosuppression

Russian Federation
Lei Li

Recruiting

Long-acting G-CSF for Febrile Neutropenia

Febrile Neutropenia | Epithelial Ovarian Cancer | Adverse Event | Cost-effectiveness | Myelosuppression Adult | Colony Stimulating Factors

China
National Taiwan University Hospital

Recruiting

Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions

Peripheral Neuropathy | Lactic Acidosis | Myelosuppression

Taiwan
Celgene

Recruiting

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Lymphoma

Japan
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3)

Bladder Cancer | Urothelial Carcinoma | Chemotherapy-induced Neutropenia | Myelosuppression Adult | Metastatic Bladder Cancer

Hungary, Spain, United States, France, Georgia
G1 Therapeutics, Inc.

Active, not recruiting

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
G1 Therapeutics, Inc.

Completed

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer

United States
G1 Therapeutics, Inc.

Active, not recruiting

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2)

Breast Cancer | TNBC - Triple-Negative Breast Cancer

United States, Spain, China, France, Australia, Georgia, Poland, Bulgaria, Moldova, Republic of, Russian Federation, Ukraine
PhytoHealth Corporation

Terminated

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

Quality of Life | Fatigue | Complementary

Taiwan
UNC Lineberger Comprehensive Cancer Center

Active, not recruiting

Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients

Breast Cancer

United States
PhytoHealth Corporation

Completed

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Neoplasm Metastasis | Neoplasm Recurrence

Taiwan
Jiangsu Simcere Pharmaceutical Co., Ltd.
G1 Therapeutics, Inc.

Completed

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

Extensive-stage Small-cell Lung Cancer

China
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1)

Colorectal Cancer Metastatic | Chemotherapeutic Toxicity | Myelosuppression-Adult

China, Spain, United States, Hungary, United Kingdom, Poland, Ukraine, Italy
Aileron Therapeutics, Inc.

Terminated

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Prevention of Chemotherapy-induced Myelosuppression

United States, Bosnia and Herzegovina, Serbia, Bulgaria
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Withdrawn

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

Osteosarcoma | Bone Metastases

United States
Taichung Tzu Chi Hospital

Completed

Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity

Myelosuppression
Hospices Civils de Lyon

Completed

DNA Repair Enzyme Signature in Head and Neck Cancer (CHEMRAD) (CHEMRAD)

Head Cancer | Neck Cancer

France
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

HIV Infections | Cytomegalovirus Retinitis

United States
G1 Therapeutics, Inc.
Bionical Emas

Approved for marketing

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapeutic Toxicity | Myelosuppression Adult
Careseng Biotech Co., Ltd.

Unknown

Careseng 1370 for Healthy Volunteers

Chemotherapy-induced Myelosuppression
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Unknown

Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

Chemotherapy-induced Neutropenia | Myelosuppression
Lei Li

Unknown

G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients

Gynecologic Cancer | Febrile Neutropenia | Chemotherapy-induced Neutropenia | Myelosuppression Adult

China
Careseng Biotech Co., Ltd.

Withdrawn

Careseng 1370 for Chemotherapy-Induced Myelosuppression

Chemotherapy-Induced Myelosuppression
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy

Malignant Glioma | Myelosuppression

United States
Myelo Therapeutics GmbH

Completed

Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia (MyeloConcept)

Breast Cancer | Myelosuppression | Chemotherapy-Induced Neutropenia

Germany
Sun Yat-sen University
Dalian Merro Pharmaceutical Co. Ltd

Unknown

A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens

Bone Marrow Diseases | Nasopharyngeal Neoplasms | Mucositis | Salivary Gland Diseases

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy

Brain Tumor

United States
Technische Universität Dresden

Unknown

Graft-versus-host Disease Associated Myelosuppression

Graft vs Host Disease | Allogenic Disease | Abnormal Hematopoiesis

Germany
Meir Medical Center

Completed

Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Israel
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Multiple Myeloma

Australia
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University

Completed

Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment

Lupus Erythematosus, Systemic | Adverse Effects

China
Rambam Health Care Campus
Zuf Globus Laboratories Ltd.

Unknown

Lifemel Honey to Reduce Leucopenia During Chemotherapy

Breast Cancer
Ziv Hospital

Unknown

Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy

Myelosuppression

Israel
Sanquin Research & Blood Bank Divisions

Completed

Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma

Thrombocytopenia | Myelosuppression | Hemato-Oncologic Patients

Netherlands

Search clinical trials for: treatment-induced myelosuppression

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations